Sublingual sildenafil in the treatment of erectile dysfunction: faster onset of action with less dose
Background: The aim of the present study was to show the efficacy and safety of sublingual sildenafil and to determine whether lower doses cause the same effect with a faster onset of action in this mode of application.
Methods: Forty consecutive patients with erectile dysfunction for more than three months were included in the study. The mean age was 55 years (range, 25-65). Serum glucose and testosterone levels, lipid profile and erectile function scores were obtained in all patients. Twenty patients received placebos and the other 20 patients received 20 mg sublingual sildenafil in a double blind randomized design.
Results: The effect of sildenafil on erection was significantly higher than that of placebo. Sixty-five percent of patients (13/20) who received sublingual sildenafil achieved satisfying erections and coitus, whereas the rate was 15% in the placebo group (3/20). The mean onset of action with sublingual sildenafil was 15.5 min and lasted for an average of 40 min. Minimal headaches, sweating and flushing were noted as the side-effects.
Conclusions: 20 mg sublingual sildenafil is safe and effective in the treatment of erectile dysfunction. Sublingual administration has some advantages as it is not effected by food ingestion and quickly appears in the circulation. These advantages provide a faster onset of action with a lower dose when compared to oral sildenafil. Sublingual use of sildenafil may be more cost-effective and possibly provides a more predictable onset of action.
Similar articles
Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Goldstein I, et al. N Engl J Med. 1998 May 14;338(20):1397-404. doi: 10.1056/NEJM199805143382001. N Engl J Med. 1998. PMID: 9580646 Clinical Trial.
Buvat J, Hatzichristou D, Maggi M, Farmer I, Martínez-Jabaloyas JM, Miller PJ, Schnetzler G. Buvat J, et al. BJU Int. 2008 Dec;102(11):1645-50. doi: 10.1111/j.1464-410X.2008.07908.x. Epub 2008 Aug 14. BJU Int. 2008. PMID: 18710446 Clinical Trial.
Pickering TG, Shepherd AM, Puddey I, Glasser DB, Orazem J, Sherman N, Mancia G. Pickering TG, et al. Am J Hypertens. 2004 Dec;17(12 Pt 1):1135-42. doi: 10.1016/j.amjhyper.2004.07.004. Am J Hypertens. 2004. PMID: 15607620 Clinical Trial.
Chew KK, Stuckey BG, Thompson PL. Chew KK, et al. Med J Aust. 2000 Mar 20;172(6):279-83. Med J Aust. 2000. PMID: 10860094 Review.
Montorsi F, Padma-Nathan H, Glina S. Montorsi F, et al. Urology. 2006 Sep;68(3 Suppl):26-37. doi: 10.1016/j.urology.2006.06.027. Urology. 2006. PMID: 17011373 Review.
Cited by
Lv Y, Luo BY, LaBadie RR, Zhu H, Feng Y, Ernst C, Crownover PH, Liang Y, Zhao Q. Lv Y, et al. Clin Pharmacol Drug Dev. 2020 Jul;9(5):573-581. doi: 10.1002/cpdd.806. Epub 2020 May 28. Clin Pharmacol Drug Dev. 2020. PMID: 32463593 Free PMC article. Clinical Trial.
Zucchi A, Costantini E, Scroppo FI, Silvani M, Kopa Z, Illiano E, Petrillo MG, Cari L, Nocentini G. Zucchi A, et al. Andrology. 2019 Nov;7(6):804-817. doi: 10.1111/andr.12683. Epub 2019 Jul 26. Andrology. 2019. PMID: 31350821 Free PMC article. Review.
Elshafeey AH, Bendas ER, Mohamed OH. Elshafeey AH, et al. AAPS PharmSciTech. 2009;10(2):361-7. doi: 10.1208/s12249-009-9213-6. Epub 2009 Mar 31. AAPS PharmSciTech. 2009. PMID: 19333762 Free PMC article.
